We report a patient who underwent peripheral blood hematopoietic progenitor (PBHP) autologous transplantation for his third SAA relapse. Although his repeated relapses were always successfully reversed by immunosuppression, he developed anaphylaxis with horse, rabbit and mouse immunoglobulins as a side-effect of his previous treatment. He was mobilized with G-CSF and underwent three leukaphereses in the period of hematologic recovery after the second relapse. Fourteen months later, he suffered his third relapse, rescued by autologous PBHP transplantation after cyclophosphamide and melphalan conditioning. At present he is 15 months after transplantation without any treatment, transfusion-independent and in good condition. Others have published the observation that sufficient PBHP can be collected at least in some patients with SAA. Our experience shows that in repeatedly relapsing SAA with no other treatment options autologous transplantation with previously collected PBHP can result in successful hematologic reconstitution.
for autologous transplantation if there is no other treatment possibility.
Case report
A 17-year-old boy was diagnosed with SAA in October 1991. SAA was diagnosed by standard criteria. 4 The patient's blood count showed severe pancytopenia with PMN 0.2 × 10 9 /l, Hb 50 g/l, platelets 8 × 10 9 /l. His trephine biopsy was described as hypocellular with less than 10% marrow cellularity, cytogenetic examination revealed a normal karyotype, and the expression of glycosyl phosphatidyl-inositol-linked proteins and a negative Ham test excluded PNH. These investigations were performed at each relapse and they always confirmed the diagnosis of SAA. As there was no available family donor, immunosuppressive treatment with rabbit ALG was started in the same month. He became transfusion independent 2 months later. In December 1992, he suffered his first SAA relapse. Because anti-rabbit antibodies were established as a result of the previous immunosuppression, he was treated with horse ALG and CsA. He became transfusion-independent again but developed not only anti-rabbit but also anti-horse antibodies and experienced anaphylaxis on both preparations of ALG. For this reason he was treated at the time of his subsequent relapse 14 months later in August 1994 with mouse OKT-3 antibody in combination with CsA. Hematopoiesis again recovered but as he developed antimouse antibodies, we were concerned about a third relapse in view of his anaphylaxis. We decided to try to mobilize and collect his PBHP at the time of transfusion independence.
The mobilization regimen was started 7 months after the last immunosuppression. It consisted of G-CSF 10 g/kg s.c. daily until the leukaphereses were finished. Daily monitoring of peripheral blood CD34
+ cells was commenced on the day 5. Cells were counted using two-color flow cytometry (Coulter Epics XL, Baxter Healthcare Corporation, Deerfield, IL, USA): directly labeled PE-conjugated MoAb against CD34 (HPCA-2; Becton Dickinson, San Jose, CA, USA) with a matched control for PBHP determination, and FITC-conjugated MoAbs against CD38, HLA-DR and CD33 (ImmunoTech, Marseille, France) for progenitor cell subset analyses. The patient underwent three leukaphereses on days 5, 6 and 7 using a continuous flow cell separator Fenwal CS 3000. With three leukaphereses, 6. /l and on day +23 G-CSF was discontinued. On day +48 the last red cell transfusion was given and since day +78 he has been platelet transfusion independent with platelets above 20 × 10 9 /l. All post-transplantation data are summarized in Table 2 . At the time of writing, the patient is 15 months after transplantation off all treatment, still /l. Trephine biopsy shows normal marrow cellularity and cytogenetic examination is normal.
Discussion
There are many data indicating stem cell abnormalities in patients with aplastic anemia. The stem cell abnormality results in a deficiency in cell numbers, as well as dysfunction in certain cases. 5, 6 Also an increased level of apoptosis in aplastic anemia marrow CD34
+ cells exists, which correlates well with disease severity. 7 On the other hand, there is clear evidence that patients with SAA must have residual hematopoietic cells because hematopoiesis largely recovers after immunosuppressive treatment. Long-term bone marrow culture results show that hematopoietic growth factors, such as G-CSF, when given after immunosuppressive therapy such as ALG and CsA, may act partly by reducing the increased level of apoptosis, resulting in improved stem cell survival. 8 Also, clinical experience with successful collection of PBHP after long-lasting G-CSF administration in patients with SAA has been published. 3 However, to our knowledge no cases of successful ABMT in patients with SAA have been reported to date. There are a few reports in the literature describing hematopoietic reconstitution after only cyclophosphamide without PBHP rescue, 9, 10 but not all patients responded to this treatment and when really high-dose cyclophosphamide was used, the median times to the last platelet transfusion and to 0.5 × 10 9 neutrophils/l were 85 and 95 days. 9 Our patient achieved more than 0.5 × 10 9 neutrophils/l on day +13 in spite of the fact that he was conditioned with high-dose cyclophosphamide together with high-dose melphalan. Fast hematopoietic reconstitution in SAA is very important for prevention of infection and bleeding. We believe that the fast recovery in our patient can be explained only by the PBHP rescue. Although many questions remain, we draw three conclusions from this limited experience: (1) 'Short' administration of G-CSF can result in mobilization of large numbers of PBHP in at least some SAA patients when they are transfusion-independent after immunosuppressive therapy. We subsequently mobilized five other transfusion-independent SAA patients and only one fulfilled the CD34 + cells criteria described for autologous transplantation. (2) CD34 + cells collected in our patient were capable of recovery after aggressive cytostatic (myeloablative?) conditioning. Although we cannot exclude the risk of future relapse, hematopoiesis rescued by these PBHP has lasted for 15 months so far. (3) It seems reasonable to try to collect and cryopreserve PBHP in SAA patients with no available donor after immunosuppressive reconstitution.
